Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Developing a biomarker to select potential patients for clinical trials of oncolytic virotherapy

FY 2014-15

Summary
Cancer accounts for more than one quarter of deaths in Canada. Current standard of care available to patients includes regiments of chemotherapy and radiotherapy. However, these treatments often cause severe side effects as they are not tumor specific. Oncolytic virotherapy provides a promising new take on cancer therapy by exploiting viruses that selectively target and kill tumor cells without causing harm to normal cell. The oncolytic virus which will be used in this research is MG-1, a genetically engineered Maraba virus which is currently in Phase1/2 clinical trials at several clinical sites. MG-1 expresses two mutations which make MG-1 a potent and efficacious oncolytic virus. Nevertheless, pre-clinical data indicates MG-1 infection in a given tumor can result in a heterogeneous response, which is predictive of potential barriers to applying oncolytic virotherapy in the clinic. Therefore, it would be advantageous to gain the ability to predict and select patients most likely to respond to the therapy prior to clinical trial enrolment. We hypothesize that assessing ex vivo infectivity of tumors can serve as a biomarker to help select the potential patients for clinical trials. This research focuses on finding a quantitative correlation between ex vivo and in vivo infectivity of tumors with MG-1 and determining if there is indeed a threshold of ex vivo infectivity required for successful in vivo infection. If we are able to predict the in vivo infectivity from ex vivo infectivity assessments, this research has the potential to help clinical oncologist to select patients and better predict outcomes of clinical trials, which will lead way with the eventual approval of oncolytic virotherapy in the clinic.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331472
Name
Son Hwan Hee
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a biomarker to select potential patients for clinical trials of oncolytic virotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Therapy; Clinical Trial; Maraba Virus; Oncolytic Rhabdovirus; Oncolytic Virus
Abstract
Cancer accounts for more than one quarter of deaths in Canada. Current standard of care available to patients includes regiments of chemotherapy and radiotherapy. However, these treatments often cause severe side effects as they are not tumor specific. Oncolytic virotherapy provides a promising new take on cancer therapy by exploiting viruses that selectively target and kill tumor cells without causing harm to normal cell. The oncolytic virus which will be used in this research is MG-1, a genetically engineered Maraba virus which is currently in Phase1/2 clinical trials at several clinical sites. MG-1 expresses two mutations which make MG-1 a potent and efficacious oncolytic virus. Nevertheless, pre-clinical data indicates MG-1 infection in a given tumor can result in a heterogeneous response, which is predictive of potential barriers to applying oncolytic virotherapy in the clinic. Therefore, it would be advantageous to gain the ability to predict and select patients most likely to respond to the therapy prior to clinical trial enrolment. We hypothesize that assessing ex vivo infectivity of tumors can serve as a biomarker to help select the potential patients for clinical trials. This research focuses on finding a quantitative correlation between ex vivo and in vivo infectivity of tumors with MG-1 and determining if there is indeed a threshold of ex vivo infectivity required for successful in vivo infection. If we are able to predict the in vivo infectivity from ex vivo infectivity assessments, this research has the potential to help clinical oncologist to select patients and better predict outcomes of clinical trials, which will lead way with the eventual approval of oncolytic virotherapy in the clinic.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Son, Hwan Hee
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~